Zoetis (NYSE:ZTS) Bolsa

Zoetis

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on), and nearly 65% from companion animal (dogs, horses, cats) products. Its us business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

Zoetis Inc

Ztest Electronics Inc

Zoetis's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) short percent of float has fallen 3.14% since its last report. The company recently reported that it has 6.90 million shares sold short, which is 1.54% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Zoetis Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1744826421_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Zoetis has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Zoetis's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Zoetis's peer group average for short interest as a percentage of float is 3.97%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into Zoetis's Recent Short Interest

Stifel analyst Jonathan Block maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Buy and lowers the price target from $180 to $165.

News

Price Target

Analyst Ratings

Stifel Maintains Buy on Zoetis, Lowers Price Target to $165

Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and raises the price target from $200 to $205.

Piper Sandler Maintains Overweight on Zoetis, Raises Price Target to $205

On Friday, the U.S. Department of Agriculture (USDA) Center for Veterinary Biologics (CVB) issued Zoetis Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labeled for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43740061/zoetis-receives-conditional-license-from-usda-for-avian-influenza-vaccine-h5n2-subtype-killed-viru" rel="noreferrer noopener">use in chickens</a>.
The conditional license was granted on the demonstration of safety, purity, and reasonable expectation of efficacy based on serology data.
Zoetis is committed to supporting poultry producers with scientific solutions for Highly Pathogenic Avian Influenza (HPAI).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43372753/eggs-prices-soar-as-bird-flu-spreads-why-experts-expect-another-45-increase-in-2025" rel="noreferrer noopener">Eggs Prices Soar As Bird Flu Spreads: Why Experts Expect Another 45% Increase In 2025</a>
The decision to vaccinate commercial poultry flocks against HPAI rests solely with national regulatory authorities in partnership with the poultry industry.
According to the USDA&#8217;s Animal and Plant Health Inspection Service, more than 150 million birds in the U.S. have been affected by HPAI since February 2022, including backyard and commercial flocks.
Conditional licenses may be renewed at the discretion of the CVB.
In 2016, the company received a conditional license for its H5N1 vaccine and a contract award for the USDA&#8217;s National Veterinary Stockpile; this vaccine was first used by the U.S. Fish &amp; Wildlife Service in 2023 to help protect California condors.
Zoetis also holds a USDA license for POULVAC&nbsp;FLUFEND i AI H5N3 RG, which has been available in smaller markets outside the U.S. and was used to help protect endangered birds in New Zealand in 2024.
Last week, Zoetis reported a fourth-quarter 2024 adjusted EPS of $1.40, up from $1.24 a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">consensus of $1.34</a>.
Zoetis expects full-year 2025 revenues of $9.225 billion—$9.375 billion (operational growth of 2%- 4%; organic operational growth of 6% to 8%) versus the <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43697905/zoetis-drops-as-2025-guidance-falls-short-of-estimates" rel="noreferrer noopener">consensus of $9.574 billion</a>.
Price Action: ZTS stock is down 0.99% at $155.96 at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43776138/kkr-raises-enilive-ownership-to-30-with-614-million-investment" target="_blank" rel="noreferrer noopener">KKR Boosts Enilive Ownership To 30% With ~$614 Million Investment: Details</a></li>
</ul>
Photo via Shutterstock

Large Cap

Health Care

General

Zoetis Avian Influenza Vaccine Secures Conditional Approval In US For Use In Chickens

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 2.1% on an annualized basis producing an average annual return of 13.25%. Currently, Zoetis has a market capitalization of $71.29 billion. 
Buying $1000 In ZTS: If an investor had bought $1000 of ZTS stock 10 years ago, it would be worth $3,455.90 today based on a price of $158.02 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739822409_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Rumors

VITL

Watching Vital Farms; Shares Move Lower After Zoetis Announced It Received Conditional License From USDA For Avian Influenza Vaccine For Chickens

CALM

Watching Cal-Maine Foods; Shares Move Lower After Zoetis Announced It Received Conditional License From USDA For Avian Influenza Vaccine For Chickens

Zoetis today announced that the U.S. Department of Agriculture (USDA), Center for Veterinary Biologics (CVB) has issued the company a conditional license for its Avian Influenza Vaccine, H5N2 Subtype, Killed Virus. The vaccine is labelled for use in chickens. The conditional license was granted on the demonstration of safety, purity, and reasonable expectation of efficacy based on serology data.
Zoetis is committed to supporting poultry producers with scientific solutions for Highly Pathogenic Avian Influenza (HPAI). The decision to vaccinate commercial poultry flocks against HPAI rests solely with national regulatory authorities in partnership with the poultry industry.
According to the USDA&#39;s Animal and Plant Health Inspection Service (<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aphis.usda.gov%2Flivestock-poultry-disease%2Favian%2Favian-influenza%2Fhpai-detections%2Fcommercial-backyard-flocks&amp;esheet=54207112&amp;newsitemid=20250214307661&amp;lan=en-US&amp;anchor=APHIS&amp;index=1&amp;md5=40a6db1454e5eb659feed3787af27f97">APHIS</a>), more than 150 million birds in the U.S. have been affected with HPAI since February 2022, including in backyard and commercial flocks. A conditional license is used to meet an emergency condition, limited market, local situation or other special circumstance and is issued for a finite period of time. Conditional licenses may be renewed at the discretion of the CVB.

Biotech

Zoetis Receives Conditional License From USDA For Avian Influenza Vaccine For Chickens, H5N2 Subtype, Killed Virus

Barclays analyst Balaji Prasad maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and raises the price target from $242 to $244.

Barclays Maintains Overweight on Zoetis, Raises Price Target to $244

WIIM

Zoetis shares are trading lower after Morgan Stanley cut its price target on the stock from $243 to $238.

Morgan Stanley analyst Erin Wright maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and lowers the price target from $243 to $238.

Morgan Stanley Maintains Overweight on Zoetis, Lowers Price Target to $238

Wall Street climbed on Thursday, even as the Producer Price Index (PPI) sharply exceeded estimates in January, reigniting concerns <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43692996/inflation-fears-mount-as-producer-prices-soar-to-35-put-fed-interest-rate-cut-on-ice">over persistent inflationary pressures. </a>
Despite the hotter-than-expected PPI reading—up 3.5% year-over-year in January, surpassing the 3.3% forecast—investors found some relief in certain PPI components that influence the Federal Reserve's preferred inflation gauge, which showed signs of <a href="https://www.benzinga.com/economics/macro-economic-events/25/02/43701823/economists-breathe-sigh-of-relief-why-producer-inflation-isnt-as-bad-as-it-seems">cooling compared to December.</a>
Investor risk appetite remained supported by expectations of ceasefire talks in Ukraine following a conversation between former President Donald Trump and Russian President Vladimir Putin a day earlier. 
By midday trading in New York, all major indices were in positive territory, with technology stocks leading the gains. Among semiconductor stocks, Intel Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) continued to rally, surging 10% after strong performances in prior sessions. 
The U.S. chipmaker benefited from renewed buying momentum following comments from Vice President J.D. Vance, who indicated that the Trump administration plans to ease regulations to accelerate AI chip innovation in the U.S.
Intel has now soared over 27% this week, tracking its best weekly performance since 1974. 
The U.S. dollar extended its decline as Treasury yields pulled back sharply, reversing Wednesday&#8217;s surge.
In commodities, gold edged up 0.4% to $2,918 per ounce, oil remained steady at $71 per barrel, and natural gas surged 2.4% to $3.66 per million British thermal units. 
Sentiment in cryptocurrency markets remained subdued, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) sliding 2.4% to trade below $96,000.
<h3 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,903.94</td>
<td>0.9%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,088.51</td>
<td>0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,493.13</td>
<td>0.3%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,261.64</td>
<td>0.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;rose 0.6% to $606.89.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.3% to $445.18.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rose 0.9% to $532.98.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.4% to $224.58.</li>
<li>The&nbsp;Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>) outperformed, up 1.1%; the&nbsp;Industrials Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>) lagged, down 1.2%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
Stocks reacting to company earnings reports included:
<ul>
<li>Cisco Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>): up 2.05%</li>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>): down 7.8%</li>
<li>Duke Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>): down 2.5%</li>
<li>American Electric Power Co. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>): down 0.6%</li>
<li>Equinix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EQIX#NASDAQ">EQIX</a>): down 1.9%</li>
<li>Moody's Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>): up 2.9%</li>
<li>Deere &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>): down 1.5%</li>
<li>PPL Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PPL#NYSE">PPL</a>): down 1.8%</li>
<li>MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>): up 17.9%</li>
<li>Paycom Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAYC#NYSE">PAYC</a>): flat</li>
<li>HubSpot Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>): up 1.6%</li>
<li>Lincoln Electric Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LECO#NASDAQ">LECO</a>): up 11.7%</li>
<li>Curtiss-Wright Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CW#NYSE">CW</a>): down 0.5%</li>
<li>West Pharmaceutical Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>): down 34%</li>
<li>CBRE Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>): up 1.1%</li>
<li>DTE Energy Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTE#NYSE">DTE</a>): up 2.4%</li>
<li>AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>): up 19.9%</li>
<li>Reddit Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>): down 8.8%. </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a></li>
</ul>
Photo: Ryan DeBerardinis via Shutterstock

Equities

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Econ #s

Economics

ETFs

$BTC

CBRE

CROX

CSCO

SPDR Dow Jones Industrial Average ETF Trust

EQIX

GEHC

HUBS

INTC

LECO

PAYC

RDDT

Select Sector SPDR-Consumer Discretionary

ZBRA

Stocks Rise Despite Hot Producer Inflation, Intel Soars, Bitcoin Drops Below $96,000: What's Driving Markets Thursday?

On Thursday, Zoetis Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) reported a fourth-quarter 2024 adjusted EPS of $1.40, up from $1.24 a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">consensus of $1.34</a>.
Adjusted net income&nbsp;for the fourth quarter of 2024 was $632 million, an increase of 11% on a reported basis and an increase of 9% on an operational basis.
The animal health firm reported sales of $2.32 billion, up 5%, inline <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43688545/zoetis-reports-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">with the consensus</a>.
On an operational&nbsp;basis, revenue for the fourth quarter of 2024 increased by 6% compared with the fourth quarter of 2023.
In October 2024, Zoetis divested its medicated feed additive (MFA) product portfolio, certain water-soluble products, and related assets.
Excluding the impact of all divested products and foreign exchange, for the fourth quarter of 2024, the organic operational growth rate was 9% and 12% for fiscal year 2024.
"We achieved 11% revenue growth in the U.S. and 10% operational revenue growth internationally, marking significant revenue milestones, and our companion animal and livestock portfolios saw strong operational revenue growth, 14% and 5%, respectively,&#8221; said Kristin Peck, chief executive officer of Zoetis.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">Big Biopharma Trails Behind The Market: JP Morgan&#8217;s 2025 Outlook on Eli Lilly, Merck, and More</a>
Guidance:&nbsp;Zoetis expects full-year 2025 revenues of $9.225 billion—$9.375 billion (operational growth of 2%- 4%; organic operational growth of 6% to 8%) versus the consensus of $9.574 billion.
&#8220;As we approach 2025, we are eager to continue the momentum we realized in 2024, and we are confident that the drivers of our success are sustainable, positioning us for continued above-market growth this year and beyond. We are guiding to full-year organic operational growth of 6% to 8% in revenue in 2025,&#8221; Peck said.
The company expects a reported net income of $2.57 billion—$2.62 billion, with adjusted net income between $2.700 billion and $2.750 billion (operational growth of 2% to 4%; organic operational growth of 6% to 8%).
Zoetis forecasts a reported EPS of $5.70-$5.80 and adjusted EPS between $6.00 and $6.10, compared to a consensus of $6.29.
Price Action: ZTS stock is down 10% at $156.17 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/02/43692253/sanofi-johnson-johnson-partnered-vaccine-against-bacterial-sepsis-flunks-late-stage-study" target="_blank" rel="noreferrer noopener">Sanofi/Johnson &amp; Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study</a></li>
</ul>
Photo: Shutterstock

Earnings

Guidance

Movers

Zoetis Drops As 2025 Guidance Falls Short Of Estimates

Zoetis shares are trading lower after the company issued FY25 guidance below estimates.

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="2" rowspan="1">2025 GUIDANCE</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Selected Line Items
(millions of dollars, except per share amounts)
</td>
<td colspan="1" rowspan="1">Full Year 2025</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$9,225 to $9,375</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operational growth(a)</td>
<td colspan="1" rowspan="1">2% to 4%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic operational growth(b)</td>
<td colspan="1" rowspan="1">6% to 8%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted cost of sales as a percentage of revenue(c)</td>
<td colspan="1" rowspan="1">Approximately 28.0%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted SG&amp;A expenses(c)</td>
<td colspan="1" rowspan="1">$2,300 to $2,350</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted R&amp;D expenses(c)</td>
<td colspan="1" rowspan="1">$680 to $690</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted interest expense and other (income)/deductions-net(c)</td>
<td colspan="1" rowspan="1">Approximately $200</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective tax rate on adjusted income(c)</td>
<td colspan="1" rowspan="1">Approximately 21%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted diluted EPS(c)</td>
<td colspan="1" rowspan="1">$6.00 to $6.10</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted net income(c)</td>
<td colspan="1" rowspan="1">$2,700 to $2,750</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operational growth(a)(d)</td>
<td colspan="1" rowspan="1">2% to 4%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic operational growth(b)(d)</td>
<td colspan="1" rowspan="1">6% to 8%</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Zoetis Expects 2025 Sales Of $9.225B-$9.375B Versus Consensus Of $9.574B, With Adjusted EPS Of $6.00-$6.10 Versus Consensus Of $6.29

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) reported quarterly earnings of $1.40 per share which beat the analyst consensus estimate of $1.34 by 4.48 percent. This is a 12.9 percent increase over earnings of $1.24 per share from the same period last year. The company reported quarterly sales of $2.32 billion which beat the analyst consensus estimate of $2.30 billion by 0.74 percent. This is a 4.70 percent increase over sales of $2.21 billion the same period last year.

Zoetis Q4 2024 Adj EPS $1.40 Beats $1.34 Estimate, Sales $2.32B Beat $2.30B Estimate

ABNB

AENT

AGIO

ALNY

AMAT

APDN

ATUS

AVNT

BENF

BFAM

BLIN

BPMC

BRKR

BTOC

CEVA

CLBT

CNVS

COHU

COIN

CYBR

DDOG

DKNG

DNOW

DXCM

EEFT

EGAN

ELME

ELVA

FBRT

FROG

GDDY

GPMT

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HIMX

HOUS

HTGC

IMPP

INFA

IRDM

IRMD

ISSC

KELYA

KELYB

KNSL

LGCY

LPTH

NTWK

NVMI

Earnings Scheduled For February 13, 2025

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$48.6K</td>
<td>44.4K</td>
<td>7.2K</td>
</tr>
<tr>
<td>ACAD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$20.00</td>
<td>$157.6K</td>
<td>109</td>
<td>1.9K</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$65.00</td>
<td>$28.5K</td>
<td>2.8K</td>
<td>840</td>
</tr>
<tr>
<td>ZTS</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$180.00</td>
<td>$43.0K</td>
<td>1.4K</td>
<td>316</td>
</tr>
<tr>
<td>EBS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$11.00</td>
<td>$43.8K</td>
<td>4</td>
<td>200</td>
</tr>
<tr>
<td>BMRN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$65.00</td>
<td>$29.2K</td>
<td>1.3K</td>
<td>159</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$245.00</td>
<td>$191.7K</td>
<td>141</td>
<td>125</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$37.00</td>
<td>$69.7K</td>
<td>1.0K</td>
<td>87</td>
</tr>
<tr>
<td>EXEL</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$17.00</td>
<td>$29.5K</td>
<td>98</td>
<td>50</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$800.00</td>
<td>$37.5K</td>
<td>843</td>
<td>31</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we notice a call option sweep that happens to be bullish, expiring in 37 day(s) on March 21, 2025. This event was a transfer of 2561 contract(s) at a $27.50 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $48.6K, with a price of $19.0 per contract. There were 44426 open contracts at this strike prior to today, and today 7236 contract(s) were bought and sold. 
• For ACAD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>), we notice a call option sweep that happens to be bullish, expiring in 128 day(s) on June 20, 2025. This event was a transfer of 901 contract(s) at a $20.00 strike. This particular call needed to be split into 8 different trades to become filled. The total cost received by the writing party (or parties) was $157.6K, with a price of $175.0 per contract. There were 109 open contracts at this strike prior to today, and today 1920 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be bearish, expiring in 64 day(s) on April 17, 2025. This event was a transfer of 20 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $28.5K, with a price of $1425.0 per contract. There were 2849 open contracts at this strike prior to today, and today 840 contract(s) were bought and sold. 
• For ZTS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 200 contract(s) at a $180.00 strike. This particular call needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $43.0K, with a price of $215.0 per contract. There were 1473 open contracts at this strike prior to today, and today 316 contract(s) were bought and sold. 
• Regarding EBS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>), we observe a call option trade with bearish sentiment. It expires in 219 day(s) on September 19, 2025. Parties traded 200 contract(s) at a $11.00 strike. The total cost received by the writing party (or parties) was $43.8K, with a price of $219.0 per contract. There were 4 open contracts at this strike prior to today, and today 200 contract(s) were bought and sold. 
• Regarding BMRN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), we observe a call option trade with bullish sentiment. It expires in 9 day(s) on February 21, 2025. Parties traded 150 contract(s) at a $65.00 strike. The total cost received by the writing party (or parties) was $29.2K, with a price of $195.0 per contract. There were 1333 open contracts at this strike prior to today, and today 159 contract(s) were bought and sold. 
• For HUM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), we notice a call option trade that happens to be bearish, expiring in 64 day(s) on April 17, 2025. This event was a transfer of 65 contract(s) at a $245.00 strike. The total cost received by the writing party (or parties) was $191.7K, with a price of $2950.0 per contract. There were 141 open contracts at this strike prior to today, and today 125 contract(s) were bought and sold. 
• For HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we notice a call option trade that happens to be bullish, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 81 contract(s) at a $37.00 strike. The total cost received by the writing party (or parties) was $69.7K, with a price of $861.0 per contract. There were 1026 open contracts at this strike prior to today, and today 87 contract(s) were bought and sold. 
• For EXEL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>), we notice a call option trade that happens to be neutral, expiring in 9 day(s) on February 21, 2025. This event was a transfer of 18 contract(s) at a $17.00 strike. The total cost received by the writing party (or parties) was $29.5K, with a price of $1640.0 per contract. There were 98 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 9 day(s) on February 21, 2025. Parties traded 5 contract(s) at a $800.00 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $7518.0 per contract. There were 843 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ACAD

BMRN

EXEL

Hims & Hers Health, Inc. Class A Common Stock

HIMS

10 Health Care Stocks With Whale Alerts In Today's Session

Piper Sandler analyst David Westenberg maintains Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) with a Overweight and lowers the price target from $210 to $200.

Piper Sandler Maintains Overweight on Zoetis, Lowers Price Target to $200

Zoetis Plans to Immediately Implement Updated Label Based on U.S. Post-Approval Experience with Librela
Company Remains Confident in the Safety and Effectiveness of Librela and Reaffirms Its Commitment to Supporting Veterinarians and Pet Owners in Helping Dogs with OA Live with Less Pain and Greater Mobility
More Than One Million Dogs in the U.S. Have Been Treated with Librela Since Its Launch in the U.S. in October 2023
Zoetis Inc. today announced that it has updated the U.S. label for Librela&#xAE; (bedinvetmab injection), following its submission of a supplement to the U.S. Food and Drug Administration (FDA). This supplement includes updated labeling based on post-approval experience with Librela in the U.S. since the product launched over a year ago. The company remains confident in the safety and effectiveness of Librela and plans to implement the updated label immediately in its ongoing commitment to supporting veterinarians and pet owners in the use of Librela. The revised label can be found by <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zoetisus.com%2Fcontent%2F_assets%2Fdocs%2Fvmips%2Fpackage-inserts%2Flibrela-prescribing-information.pdf&amp;esheet=54198868&amp;newsitemid=20250203254176&amp;lan=en-US&amp;anchor=clicking+here&amp;index=1&amp;md5=040088fd7159d9cc6b86d16e0b9d750a">clicking here</a>.
Librela, a once-monthly injectable monoclonal antibody for the control of pain associated with osteoarthritis (OA) in dogs, was approved for use by the FDA in May 2023 and launched in the U.S. in October 2023. It has been used to treat more than one million dogs in the U.S.
Zoetis has been engaged with the FDA to review post-launch, real-world drug experience data reported to the agency and collected through Zoetis' pharmacovigilance monitoring of its products' safety and efficacy. Label updates in the pharmaceutical space are not uncommon, particularly in the first few years after a launch in response to real-world experience data.

Zoetis Announces Updated Librela Label Based On U.S. FDA Post-Approval Data

Press Releases

Zoetis to Participate in the Piper Sandler 36th Annual Healthcare Conference

Zoetis Declares First Quarter 2025 Dividend; Board Approves 16% Payment Increase

Zoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2024 Financial Results

Is Zoetis Inc. (NYSE: ZTS) Overvalued? Or Is It Worth Buying Now?

Zoetis Announces U.S. Label Update for Librela® (bedinvetmab injection), a Treatment to Control Canine Osteoarthritis (OA) Pain

Zoetis Declares Second Quarter 2025 Dividend

Zoetis Reports Fourth Quarter and Full Year 2024 Results

Zoetis Receives Conditional License from USDA for Avian Influenza Vaccine, H5N2 Subtype, Killed Virus

Zoetis to Participate in Upcoming Investor Conferences

Zoetis to Host Webcast and Conference Call on First Quarter 2025 Financial Results

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Zoetis

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL